Fig. 5 Maraba induces antitumor T cell immunity.

Slides:

Advertisements

Similar presentations

Fig. 2. LUM015 fluorescently labels tumor cells in mouse models of STS and breast cancer. LUM015 fluorescently labels tumor cells in mouse models of STS.

Advertisements

Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.

Cognate interaction with antigen-specific T cells is required for the response of IgG-type memory B cells. Cognate interaction with antigen-specific T.

Volume 15, Issue 8, Pages (August 2007)

Fig. 2. VEGF-C/VEGFR-3 signaling increases responsiveness of melanoma to immunotherapy. VEGF-C/VEGFR-3 signaling increases responsiveness of melanoma to.

Fig. 6. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex vivo. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex.

Fig. 4. aPD-1 mAb transfer to macrophages is mediated by FcγRs.

Fig. 1 Localized treatment of TNBC cancers kills tumor cells and minimizes the metastatic burden. Localized treatment of TNBC cancers kills tumor cells.

Fig. 8. In vivo suppression of MM by CMLD

Fig. 2 Maraba treatment results in complete responses in the window of opportunity setting. Maraba treatment results in complete responses in the window.

Fig. 1 pDCs infiltrate the skin of SSc patients and spontaneously secrete IFN-α and CXCL4. pDCs infiltrate the skin of SSc patients and spontaneously secrete.

Molecular Therapy - Oncolytics

Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.

Fig. 3 BX795 blocks the synthesis of HSV-1 virions.

Maraba treatment sensitizes 4T1 tumors to immune checkpoint blockade

Fig. 7. The PD-L1 defect is evident in HSPCs from T1D patients.

Fig. 5. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic mice. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic.

Fig. 5. Immunohistochemistry of the tumor microenvironment in GBM specimens before and after CART-EGFRvIII infusion. Immunohistochemistry of the tumor.

Fig. 5 A competent Fc is required for the antitumor immune response.

Fig. 4 Expression of cleaved caspase 3, PD-L1, and PD-1 in HGGs after reovirus treatment. Expression of cleaved caspase 3, PD-L1, and PD-1 in HGGs after.

Fig. 5. Vascularization of human liver seed grafts.

Fig. 4. Antitumor efficacy of ERY974 against various cancer types.

Volume 13, Issue 1, Pages (January 2006)

Fig. 5 Combination intravenous reovirus and checkpoint inhibition in an orthotopic syngeneic brain tumor model. Combination intravenous reovirus and checkpoint.

Type 1 immunity drives metabolic disease but protects against NAFLD

Fig. 4. MATE1 transcription in RCC.

Fig. 3 In situ vaccination with CpG and anti-OX40 is therapeutic in a spontaneous tumor model. In situ vaccination with CpG and anti-OX40 is therapeutic.

Fig. 2. Circulating VEGF in GCA patients up-regulates microvascular endothelial Jagged1. Circulating VEGF in GCA patients up-regulates microvascular endothelial.

Fig. 5. Accelerated NASH-driven fibrogenesis in obese IFN-γ−/− mice is characterized by severe eosinophilic inflammation during TGF-β blockade. Accelerated.

Fig. 3. Recovery of AVP-deficient rats from anemia induced by sublethal irradiation. Recovery of AVP-deficient rats from anemia induced by sublethal irradiation.

Fig. 4. Genetically engineered PD-L1

Fig. 8 Combining M7824 with radiation or chemotherapy enhances antitumor efficacy. Combining M7824 with radiation or chemotherapy enhances antitumor efficacy.

Fig. 5 Local gel scaffold for T cell memory response.

Fig. 3 M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. M7824 inhibits tumor growth and metastasis and provides long-term.

Fig. 7 Improvement of clinical score and axon pathology by nasal IL-4 treatment during chronic EAE. Improvement of clinical score and axon pathology by.

IFN-γ induces TNF family ligand protein expression in vitro and in vivo. IFN-γ induces TNF family ligand protein expression in vitro and in vivo. (A and.

Fig. 7 CSPG4-high GBMs show more microglia than CSPG4-low GBMs and express TNFα. CSPG4-high GBMs show more microglia than CSPG4-low GBMs and express TNFα.

Stroke induces atheroprogression via the RAGE-signaling pathway

Fig. 4 TNF-α up-regulates Fas/Fap-1 expression to promote IL-1RA–sEV release in murine MSCs. TNF-α up-regulates Fas/Fap-1 expression to promote IL-1RA–sEV.

Fig. 1 CpG induces the expression of OX40 on CD4 T cells.

Fig. 6. pKL cells revert hyperglycemia in NOD mice in vivo.

TLR9 deficiency promotes aberrant T cell and myeloid dendritic cell (DC) phenotype in imiquimod-induced autoimmunity. TLR9 deficiency promotes aberrant.

Fig. 7. Genetic ablation of UCP2 compromised the protective effect of exogenous irisin on lung IR injury. Genetic ablation of UCP2 compromised the protective.

Fig. 1 Effect of preinfection β7Hi CD45RA−CD4+ T cell frequency on HIV acquisition risk in CAPRISA 004 study. Effect of preinfection β7Hi CD45RA−CD4+ T.

Fig. 7. mRIPO therapy restricts tumor growth and produces antigen-specific antitumor immunity. mRIPO therapy restricts tumor growth and produces antigen-specific.

CXCR5 expression accelerates Eμ-Tcl1 leukemogenesis and is indispensable for tumor cell recruitment to lymphoid B-cell follicles. CXCR5 expression accelerates.

Fig. 3. VEGFR-3 signaling increases infiltration of naïve T cells in a CCR7-dependent manner. VEGFR-3 signaling increases infiltration of naïve T cells.

Fig. 2. Exposure of both TCR and CAR antigens diminishes efficacy of CAR8 but not CAR4 cells. Exposure of both TCR and CAR antigens diminishes efficacy.

Fig. 2 Adoptive transfer of adult Ox40−/− splenocytes into adult HBVEnvRag−/− mice alters hepatic inflammation, HBsAg clearance, HBsAb seroconversion,

Fig. 6 Innate and adaptive immunity, but not ADCC, contributes to M7824 antitumor activity. Innate and adaptive immunity, but not ADCC, contributes to.

Fig. 4. Dabrafenib and trametinib changed the cellular components of the tumor microenvironment. Dabrafenib and trametinib changed the cellular components.

Fig. 3 CSF1 is expressed in human melanoma.

Fig. 1. Exposure to P. duboscqi uninfected sand flies (USFs) induces an anti-saliva immunity that protects NHP from vector-transmitted CL. Exposure to.

Fig. 5 BRD0705 induces differentiation in AML cell lines and primary patient samples through GSK3α-selective inhibition. BRD0705 induces differentiation.

Fig. 5 Extended local release of R848 increases the number of innate and adaptive antitumor immune cells and cytokines. Extended local release of R848.

Fig. 5 Treatment with an OX40 agonist antibody of 3-week-old HBVtgRag−/− mice or mice with chronic HBV disease results in an altered immune response to.

Serial vaccination with 32Dp210-derived whole cell vaccines in non-tumor-bearing mice stimulates robust antileukemic cytolytic activity. Serial vaccination.

Fig. 6 In utero injection of inflammatory cytokines or adoptive transfer of activated T cells leads to pregnancy loss. In utero injection of inflammatory.

SEMA3C regulates prostate cancer cell growth

Fig. 3 M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. M7824 inhibits tumor growth and metastasis and provides long-term.

Fig. 5 A competent Fc is required for the antitumor immune response.

Fig. 8 Combining M7824 with radiation or chemotherapy enhances antitumor efficacy. Combining M7824 with radiation or chemotherapy enhances antitumor efficacy.

Fig. 4. Genetically engineered PD-L1

Fig. 3 BMS blocks functional responses in primary immune cells driven by IL-23 and IL-12. BMS blocks functional responses in primary immune.

Fig. 2 In situ vaccination of CpG in combination with anti-OX40 antibody cures established local and distant tumors. In situ vaccination of CpG in combination.

BMS blocks functional responses in primary immune cells driven by IFNα

Fig. 3 Local Maraba treatment of TNBC tumors provides long-term systemic protection. Local Maraba treatment of TNBC tumors provides long-term systemic.

Fig. 5 Increased myometrial cell contractility in response to fetal T cells from preterm infants. Increased myometrial cell contractility in response to.

Fig. 6 Antitumor effect on tumor growth and pulmonary metastasis of CSSD-9 in vivo. Antitumor effect on tumor growth and pulmonary metastasis of CSSD-9.

LSECtin, expressed by B16 cells, inhibits the tumor-specific immune responses both in vivo and in vitro. LSECtin, expressed by B16 cells, inhibits the.

Presentation transcript:

Fig. 5 Maraba induces antitumor T cell immunity. Maraba induces antitumor T cell immunity. (A) Migration of splenocytes induced by conditioned medium from uninfected or infected 4T1 or EMT6 cells (n = 4 experimental replicates). (B) The same experiment was performed in the 4T1 cell line in the presence of control or blocking antibodies (Ab) (n = 4 experimental replicates; unpaired two-tailed t test with Welch’s correction, *P < 0.05, **P < 0.01, and ***P < 0.001). (C and D) Percentage of cells within 4T1 tumors that stained positive for CD45 as quantified by flow cytometry 10 days (C) or 2 days (D) after Maraba treatment with and without CXCR3-blocking antibodies (n = 5 mice; unpaired two-tailed t test with Welch’s correction, **P < 0.01 and ***P < 0.001). (E) Immunohistological assessment of CD3+ cells in 4T1 tumors at the time of resection in the tumor rechallenge model. Scale bars, 100 μm. (F) Interferon-γ (IFN-γ) ELISPOT (enzyme-linked immunospot) analysis of splenocytes harvested 10 days after treatment from mice treated with Maraba for five consecutive days (n = 3 to 5 mice per group). Restim, ex vivo restimulation with cells. (G) The same experiment was repeated with or without blocking antibodies administered intraperitoneally (n = 5 mice per group; unpaired two-tailed t test, **P < 0.01 and ***P < 0.001). The cells were restimulated ex vivo with EMT6 or 4T1 cells. IFN-αR1, IFN-α receptor 1. Marie-Claude Bourgeois-Daigneault et al., Sci Transl Med 2018;10:eaao1641 Published by AAAS